All In Biotech

Drug Trial Radar · NCT00943397

Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma (0476-232)

A Multicenter, Open-Label, Controlled, Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma

Last checked: Nov 20, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 190 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

190

Actual

Start

Apr 2001

Primary completion

Oct 2001

Study completion Nov 2001

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Jul 22, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 6 months, up to 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients were treated with either montelukast 4 mg oral granules or usual care. Patients who completed Protocol MK0476-176-01 (NCT00943683) had the option to enroll in this study. Additionally, patients with asthma who were 6 to 11 months of age and who had not participated in Protocol MK0476-176-01, could also enroll.

Conditions

  • Asthma

Interventions

  • montelukast sodiumDrug

    Montelukast 4 mg oral granules mixed with 1 tablespoon soft food once daily at bedtime for 52 weeks

  • Comparator: Usual CareDrug

    Usual care defined as inhaled/nebulized cromolyn or inhaled nedocromil or inhaled/nebulized corticosteroids, according to the investigator's usual clinical practice for 52 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Clinical Adverse Experiences (CAEs) Reported by Patients With up to 52 Weeks of TreatmentTime frame: Up to 52 weeks of treatment

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.